Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Autor: Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Aurélie Catteau, Lisa Salvatore, Sara Lonardi, Isabelle Boquet, Stefano Tamberi, Federica Marmorino, Roberto Moretto, Margherita Ambrosini, Emiliano Tamburini, Giampaolo Tortora, Alessandro Passardi, Francesca Bergamo, Alboukadel Kassambara, Thomas Sbarrato, Federica Morano, Giuliana Ritorto, Beatrice Borelli, Alessandra Boccaccino, Veronica Conca, Mirella Giordano, Clara Ugolini, Jacques Fieschi, Alexia Papadopulos, Clémentine Massoué, Giuseppe Aprile, Lorenzo Antonuzzo, Fabio Gelsomino, Erika Martinelli, Nicoletta Pella, Gianluca Masi, Gabriella Fontanini, Luca Boni, Jérôme Galon, Chiara Cremolini

Publikováno v: The Lancet Oncology. 23:876-887

Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both an active combination chemotherapy (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e319f29a71b733c7203ed171aea9b78
https://doi.org/10.1016/s1470-2045(22)00274-1

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Autor: Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, Sara Lonardi, Fotios Loupakis, Filippo Pietrantonio, Roberto Bordonaro, Tiziana Pia Latiano, Emiliano Tamburini, Daniele Santini, Alessandro Passardi, Federica Marmorino, Roberta Grande, Giuseppe Aprile, Alberto Zaniboni, Sabina Murgioni, Cristina Granetto, Angela Buonadonna, Roberto Moretto, Salvatore Corallo, Stefano Cordio, Lorenzo Antonuzzo, Gianluca Tomasello, Gianluca Masi, Monica Ronzoni, Samantha Di Donato, Chiara Carlomagno, Matteo Clavarezza, Giuliana Ritorto, Andrea Mambrini, Mario Roselli, Samanta Cupini, Serafina Mammoliti, Elisabetta Fenocchio, Enrichetta Corgna, Vittorina Zagonel, Gabriella Fontanini, Clara Ugolini, Luca Boni, Alfredo Falcone, Filippo Guglielmo Maria De Braud, Evaristo Maiello, Giovanni Luca Frassineti, Teresa Gamucci, Francesco Di Costanzo, Luca Gianni, Patrizia Racca, Giacomo Allegrini, Alberto Sobrero, Massimo Aglietta, Enrico Cortesi, Domenico Cristiano Corsi, Alberto Ballestrero, Andrea Bonetti, Francesco Di Clemente, Enzo Ruggeri, Fortunato Ciardiello, Marco Benasso, Stefano Vitello, Saverio Cinieri, Stefania Mosconi, Nicola Silvestris, Antonio Frassoldati, Samantha Cupini, Alessandro Bertolini, Giampaolo Tortora, Carmelo Bengala, Daris Ferrari, Antonia Ardizzoia, Carlo Milandri, Silvana Chiara, Gianpiero Romano, Stefania Miraglia, Laura Scaltriti, Francesca Pucci, Livio Blasi, Silvia Brugnatelli, Luisa Fioretto, Angela Stefania Ribecco, Raffaella Longarini, Michela Frisinghelli, Maria Banzi

Publikováno v: The Lancet Oncology. 21:497-507

Summary Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4c063b870a6358d03a96a6c6d9271c5
https://doi.org/10.1016/s1470-2045(19)30862-9

Tailoring chemotherapy supply according to patients’ preferences: a quantitative method in colorectal cancer care

Autor: Rosalba Rosato, Sara Bustreo, Daniela Di Cuonzo, Eva Pagano, Giuliana Ritorto, Patrizia Racca, Laura Fanchini

Publikováno v: Current Medical Research and Opinion. 36:73-81

Objectives: The aim of this study was to conduct a discrete choice experiment with patients affected by colorectal cancer to understand their preferences for different attributes of the chemotherapy supply. Our overall goal is to provide evidence on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a6b9f379db031f7e68e34b4a6210bc6
https://doi.org/10.1080/03007995.2019.1670475

Response shift in health-related quality of life measures in the presence of formative indicators

Autor: Rosalba Rosato, Patrizia Racca, Laura Fanchini, Sara Bustreo, Giuliana Ritorto, Daniela Di Cuonzo, Silvia Testa

Publikováno v: Health and Quality of Life Outcomes
Health and Quality of Life Outcomes, Vol 19, Iss 1, Pp 1-11 (2021)

Background Response shift (RS) has been defined as a change in the meaning of an individual’s self-evaluation that needs to be accounted for when assessing longitudinal changes in health-related quality of life (HRQoL). RS detection through structu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::752b3c46fa6d9900d55f0741e441fb08
http://hdl.handle.net/2318/1766022

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study

Autor: Alessandra Raimondi, Lorenza Rimassa, Francesca Bergamo, Carlotta Antoniotti, Matteo Clavarezza, Monica Niger, Vincenzo Adamo, Roberto Murialdo, Filippo Pietrantonio, Massimo Di Maio, Andrea Sartore-Bianchi, Giorgia Peverelli, Maria Antista, Saverio Cinieri, Monica Giordano, Fausto Petrelli, Marco Tampellini, Salvatore Corallo, Maria Di Bartolomeo, Sara Lonardi, Lorenzo Antonuzzo, Gianluca Tomasello, Filippo de Braud, Raffaella Longarini, Giuliana Ritorto, Federica Morano, Alberto Zaniboni

Background Quality of life (QoL) patient-reported outcomes (PROs) data from pivotal first-line trials in metastatic colorectal cancer (mCRC) are poor. The Valentino study showed that de-escalation to single-agent panitumumab after 4-month induction w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cece534f8a34f890c25303db0d3ec650
http://hdl.handle.net/2318/1770066